医学
替罗非班
改良兰金量表
冲程(发动机)
入射(几何)
队列
麻醉
内科学
缺血性中风
缺血
心肌梗塞
机械工程
光学
物理
工程类
经皮冠状动脉介入治疗
作者
Wei Li,Lin Li,Meng Zhang,Ya Wu,Chengchun Liu,Xiaoshu Li,Shuhan Huang,Chun‐Rong Liang,Yanjiang Wang,Jinhua Chen,Wuwei Feng
出处
期刊:Stroke
[Ovid Technologies (Wolters Kluwer)]
日期:2016-10-01
卷期号:47 (10): 2649-2651
被引量:87
标识
DOI:10.1161/strokeaha.116.014413
摘要
We investigated whether early initiation of tirofiban, a glycoprotein IIb/IIIa antagonist, is safe, can reduce the risk of reocclusion, and improve outcomes in acute ischemic stroke patients after alteplase.Forty-one patients received alteplase followed by intravenous tirofiban infusion for at least 24 hours. The incidence of symptomatic intracranial hemorrhage, systematic bleedings, and death was recorded. The National Institutes of Health stroke scale score was evaluated at 24 hours and at day 7 (or discharge). Modified Rankin scale was assessed at 3 months. Outcomes for these patients were compared with a propensity score-matched historical cohort with alteplase only.The incidence of symptomatic intracranial hemorrhage, death, or systematic bleedings (P=1.00) was not increased in the alteplase/tirofiban group. At 24 hours, fewer patients experienced reocclusion in the alteplase/tirofiban group (2.4% versus 22.0%; P=0.025). At day 7 or discharge, the median National Institutes of Health stroke scale score was significantly lower in the alteplase/tirofiban group (1 versus 6; P=0.002). At 3 months, more patients had favorable outcomes of modified Rankin scale 0 to 1 (70.7% versus 46.2%; P=0.026).Intravenous tirofiban immediately after alteplase seems to be safe and potentially more effective when compared with alteplase alone for selected stroke patients.URL: http://www.chictr.org.cn/. Unique identifier: ChiCTR-TRC-14004630.
科研通智能强力驱动
Strongly Powered by AbleSci AI